Australia's CSL posts strong sales and revenues growth for 2016/17

16 August 2017

Australian biotech firm CSL Limited (ASX: CSL) today announced a net profit after tax (NPAT) of $1,337 million (all figures US dollars) for the 12 months ended June 30, 2017. Underlying NPAT was up 24% and underlying earnings per share (EPS) grew 26%, both on a constant currency (CC) basis.

Revenue for the fiscal year was $6,923 million, a rise of 15% at CC. Earnings before interest and tax (EBIT) came in at $1,769 million, up 23% CC, and earnings per share were $2.94, an underlying increase of 26%.

At its CSL Behring business unit, the key growth driver was Privigen, the company’s intravenous immunoglobulin product for which demand has been strong in both the USA and Europe. Privigen sales grew at 21% at constant currency. Privigen’s exceptional performance was driven by significant growth in the Speciality Pharmacy segment, Privigen’s expanded indication to include its use in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Europe as well as substantial market share gains due to competitor supply disruptions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK